RCKT vs XOMA
RCKT: Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | RCKT | XOMA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.25 | $40.17 | |
| Market cap as of 2026-08-01 | $355M | $504M | |
| P/E as of 2026-08-01 | n/a | 21.00 | |
| Net margin as of 2026-08-01 | n/a | +69.6% | |
| Gross margin as of 2026-08-01 | n/a | +100.0% | |
| Operating margin as of 2026-08-01 | n/a | +61.3% | |
| ROE as of 2026-08-01 | -70.8% | +32.4% | XOMA higher |
| ROA as of 2026-08-01 | -59.6% | +13.1% | XOMA higher |
| Debt / equity as of 2026-08-01 | 0.09 | 0.91 | RCKT lower |
| Revenue growth (YoY) as of 2026-08-01 | n/a | +13.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +105.3% | |
| Dividend yield as of 2026-08-01 | n/a | +0.8% | |
| Beta as of 2026-08-01 | 0.47 | 0.88 | |
| 1-year return as of 2026-07-27 close | +3.5% | +57.7% | XOMA higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.